scholarly article | Q13442814 |
P356 | DOI | 10.1097/00002030-200009080-00006 |
P698 | PubMed publication ID | 10997395 |
P50 | author | Mario Clerici | Q37839199 |
Lucia Lopalco | Q43112481 | ||
Jorma Hinkula | Q45362376 | ||
Rupert Kaul | Q63355154 | ||
Kristina Broliden | Q65998322 | ||
P2093 | author name string | J J Bwayo | |
F Plummer | |||
C Devito | |||
P2860 | cites work | Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells | Q28270680 |
P433 | issue | 13 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | HIV | Q15787 |
P304 | page(s) | 1917-1920 | |
P577 | publication date | 2000-09-01 | |
P1433 | published in | AIDS | Q4651863 |
P1476 | title | Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate | |
P478 | volume | 14 |
Q37054470 | A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice |
Q40220988 | A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles |
Q37535105 | A mucosally targeted subunit vaccine candidate eliciting HIV-1 transcytosis-blocking Abs. |
Q36759980 | A systems biology examination of the human female genital tract shows compartmentalization of immune factor expression |
Q47802627 | Acute sinusitis: Finnish clinical practice guidelines |
Q37472898 | An African perspective on mucosal immunity and HIV-1. |
Q33856326 | Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission |
Q91734951 | Anti-chlamydia IgG and IgA are insufficient to prevent endometrial chlamydia infection in women, and increased anti-chlamydia IgG is associated with enhanced risk for incident infection |
Q89712283 | CCR10 expression is required for the adjuvant activity of the mucosal chemokine CCL28 when delivered in the context of an HIV-1 Env DNA vaccine |
Q36166987 | CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects |
Q37237797 | Cervicovaginal HIV-1-neutralizing immunoglobulin A detected among HIV-1-exposed seronegative female partners in HIV-1-discordant couples |
Q37856708 | Coming of age: reconstruction of heterosexual HIV-1 transmission in human ex vivo organ culture systems |
Q36547166 | Comparative Evaluation of HIV-1 Neutralization in External Secretions and Sera of HIV-1-Infected Women |
Q36943319 | Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments |
Q39933471 | Excretion of human immunodeficiency virus type 1 through polarized epithelium by immunoglobulin A. |
Q39285745 | Exploration of potential mechanisms of hepatitis C virus resistance in exposed uninfected intravenous drug users. |
Q57997576 | Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers |
Q36342033 | Global human genetics of HIV-1 infection and China |
Q36874604 | HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. |
Q33939974 | HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificities |
Q37347345 | HIV-1-Neutralizing IgA Detected in Genital Secretions of Highly HIV-1-Exposed Seronegative Women on Oral Preexposure Prophylaxis |
Q40405474 | HIV-1-infected blood mononuclear cells form an integrin- and agrin-dependent viral synapse to induce efficient HIV-1 transcytosis across epithelial cell monolayer. |
Q73280309 | HIV-gp160 modulates differentially the productionin vitroof IgG, IgA and cytokines by blood and tonsil B lymphocytes from HIV-negative individuals |
Q28731648 | HIV-neutralizing activity of cationic polypeptides in cervicovaginal secretions of women in HIV-serodiscordant relationships |
Q37344236 | HIV/AIDS vaccines: a need for new concepts? |
Q33609816 | Hiv-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants |
Q34449068 | How can we design better vaccines to prevent HIV infection in women? |
Q45385937 | Human immunodeficiency virus (HIV) antigens and RNA in HIV-seronegative women with cervical intraepithelial neoplasia |
Q30404393 | Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review |
Q53002224 | Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate. |
Q34198897 | IgA and the IgA Fc receptor. |
Q35057901 | IgM Repertoire Biodiversity is Reduced in HIV-1 Infection and Systemic Lupus Erythematosus |
Q37720097 | Immune correlates of HIV exposure without infection in foreskins of men from Rakai, Uganda |
Q33915790 | Immune responses to HIV and SIV in mucosal tissues: 'location, location, location'. |
Q34712244 | Immune responses to HIV in the female reproductive tract, immunologic parallels with the gastrointestinal tract, and research implications |
Q36017750 | Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration |
Q35636425 | Immunoglobulin A antibodies against internal HIV-1 proteins neutralize HIV-1 replication inside epithelial cells |
Q33852361 | Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients |
Q36099546 | Immunologic uniqueness of the genital tract: challenge for vaccine development |
Q36487349 | Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8. |
Q39551647 | Increased Serpin A5 levels in the cervicovaginal fluid of HIV-1 exposed seronegatives suggest that a subtle balance between serine proteases and their inhibitors may determine susceptibility to HIV-1 infection |
Q33611645 | Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy |
Q54492375 | Induction of serum and mucosal FIV-specific immune responses by intranasal immunization with p24Gag. |
Q33788701 | Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation |
Q35794634 | Insights into the role of host genetic and T-cell factors in resistance to HIV transmission from studies of highly HIV-exposed Thais |
Q34976881 | Intranasal vaccination using interleukin-12 and cholera toxin subunit B as adjuvants to enhance mucosal and systemic immunity to human immunodeficiency virus type 1 glycoproteins. |
Q55877037 | Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy |
Q46193132 | Male circumcision and prevention of HIV and sexually transmitted infections |
Q37734746 | Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease |
Q37015889 | Microbial Translocation and B Cell Dysfunction in Human Immunodeficiency Virus Disease |
Q33911540 | Mucosal correlates of protection in HIV-1-exposed sero-negative persons |
Q36863855 | Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women |
Q35108719 | Mucosal immunity and vaccination against HIV |
Q34275424 | Mucosal immunity in the female genital tract, HIV/AIDS |
Q37137068 | Mucosal immunity to HIV: a review of recent literature |
Q36464264 | Mucosal immunization with virus-like particles of simian immunodeficiency virus conjugated with cholera toxin subunit B. |
Q45886136 | Multigene/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery |
Q35018133 | Natural anti-CCR5 antibodies in HIV-infection and -exposure |
Q28548507 | Non-Cationic Proteins Are Associated with HIV Neutralizing Activity in Genital Secretions of Female Sex Workers |
Q37052319 | Not just sheer luck! Immune correlates of protection against HIV-1 infection. |
Q35653717 | Oral delivery of wafers made from HBsAg-expressing maize germ induces long-term immunological systemic and mucosal responses. |
Q35705707 | Oral immunization with recombinant listeria monocytogenes controls virus load after vaginal challenge with feline immunodeficiency virus |
Q54639912 | Polymorphisms in the interleukin-4 receptor alpha chain gene influence susceptibility to HIV-1 infection and its progression to AIDS. |
Q34437201 | Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals |
Q35683986 | Randomized Cross-Sectional Study to Compare HIV-1 Specific Antibody and Cytokine Concentrations in Female Genital Secretions Obtained by Menstrual Cup and Cervicovaginal Lavage |
Q34598141 | Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes |
Q62487341 | Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in Women Chronically Infected with HIV-1 |
Q30601090 | Recombinant expression, purification, and biophysical characterization of the transmembrane and membrane proximal domains of HIV-1 gp41. |
Q37143750 | Repeated vaginal administration of trimeric HIV-1 clade C gp140 induces serum and mucosal antibody responses |
Q45394795 | Salivary human immunodeficiency virus (HIV)-1-specific immunoglobulin A in HIV-1-exposed infants in Kenya |
Q45724156 | Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infection |
Q33548718 | Setting of methods for analysis of mucosal antibodies in seminal and vaginal fluids of HIV seropositive subjects from Cambodian and Italian cohorts |
Q37617455 | Sublingual Priming with a HIV gp41-Based Subunit Vaccine Elicits Mucosal Antibodies and Persistent B Memory Responses in Non-Human Primates |
Q33595068 | The Membrane-Proximal Region of C-C Chemokine Receptor Type 5 Participates in the Infection of HIV-1. |
Q47107303 | The Role of Natural Antibodies to CC Chemokine Receptor 5 in HIV Infection |
Q30408103 | The development of an AIDS mucosal vaccine. |
Q64379779 | The gp41 epitope, QARVLAVERY, is highly conserved and a potent inducer of IgA that neutralizes HIV-1 and inhibits viral transcytosis |
Q33301326 | The mucosae-associated epithelial chemokine (MEC/CCL28) modulates immunity in HIV infection |
Q35591075 | The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression |
Q37348636 | Transcytosis-blocking abs elicited by an oligomeric immunogen based on the membrane proximal region of HIV-1 gp41 target non-neutralizing epitopes. |
Q37309287 | Unbiased proteomics analysis demonstrates significant variability in mucosal immune factor expression depending on the site and method of collection |
Q36415776 | Understanding the "lucky few": the conundrum of HIV-exposed, seronegative individuals. |
Q34467932 | Use of cervicovaginal fluid for the identification of biomarkers for pathologies of the female genital tract. |
Search more.